Publicacions en què col·labora amb MARCOS GONZÁLEZ DÍAZ (24)

2020

  1. Measures to Maintain a SARS-CoV-2 Negative Inpatient Hematological Unit in the Midst of the COVID-19 Pandemic

    Frontiers in Medicine, Vol. 7

  2. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

    Blood Cancer Journal, Vol. 10, Núm. 2

2017

  1. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    Leukemia, Vol. 31, Núm. 10, pp. 2094-2103

  2. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  3. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

    Hematological Oncology, Vol. 35, Núm. 4, pp. 746-751

2015

  1. The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution

    Leukemia

2014

  1. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

    Leukemia, Vol. 28, Núm. 2, pp. 391-397

  2. Late differentiation syndrome in acute promyelocytic leukemia: A challenging diagnosis

    Hematology Reports, Vol. 6, Núm. 4, pp. 75-77

2013

  1. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

    British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234

2012

  1. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status

    Leukemia, Vol. 26, Núm. 12, pp. 2521-2529

2010

  1. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

    Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458

2007

  1. Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism

    Thrombosis Research, Vol. 119, Núm. 6, pp. 691-698

2003

  1. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning

    Bone Marrow Transplantation, Vol. 31, Núm. 5, pp. 387-392

2002

  1. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation

    Leukemia, Vol. 16, Núm. 8, pp. 1423-1431

  2. Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis

    British Journal of Haematology, Vol. 117, Núm. 4, pp. 890-892

2001

  1. Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation

    Bone Marrow Transplantation, Vol. 28, Núm. 7, pp. 665-672

  2. p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies

    Hematology Journal, Vol. 2, Núm. 3, pp. 146-149

2000

  1. De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis

    Leukemia, Vol. 14, Núm. 1, pp. 183-187

  2. Status of methylation of p16 gene in multiple myeloma: A comparative study of three methods for its detection

    Clinical Biochemistry, Vol. 33, Núm. 5, pp. 415-418

  3. The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation

    Leukemia, Vol. 14, Núm. 8, pp. 1493-1499